dulaglutide vs tirzepatide π‘ New insight in diabetes care: In patients with T2DM and ASCVD, the SURPASS-CVOT trial found that was noninferior to for major cardiovascular events (12.2% 13.1%; HR 0.92). What Long-awaited SURPASS-CVOT: Cardiovascular Outcomes with
Pay in 4 interest-free payments of $5.04 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Aug 1 - Aug 6




























